Under construction – not a live service
Sign in
Taking people in CanadaNo phase

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Key facts

Where
Toronto, CanadaSee the site

Where in Canada

  • Princess Margaret Cancer CentreToronto, CanadaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Health Network, Toronto
Trial code
NCT05196087
Record updated
28 September 2026
Original description
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.Read full original descriptionShow less

Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.

Inclusion: Patients with histological confirmation of a solid tumor; Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment; Patient must be ≥ 18 years old; All patients must have signed and dated an informed consent form.

Exclusion: None.

ClinicalTrials.gov NCT05196087